

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

APPENDIX 5
FORMS RELATING TO LISTING
FORM F
GEM
COMPANY INFORMATION SHEET

Case Number: _____

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: China Biotech Services Holdings Limited

Stock code (ordinary shares): 8037

This information sheet contains certain particulars concerning the above company (the “Company”) which is listed on GEM of The Stock Exchange of Hong Kong Limited (the “Exchange”). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”). They will be displayed at the GEM website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 30 May 2023.

A. General

Place of incorporation: Incorporated in the Cayman Islands and continued in Bermuda

Date of initial listing on GEM: 17 June 2004

Name of Sponsor(s): N/A

Names of directors:
(please distinguish the status of the directors
- Executive, Non-Executive or Independent
Non-Executive)

Executive Directors
Mr. LIU Xiaolin (Chairman)
Mr. HE Xun
Mr. HUANG Song
Ms. CHUI Hoi Yam

Independent Non-executive Directors
Mr. YAN Guoxiang
Dr. HO Ivan Chun Kit
Mr. QIAN Hongji

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name(s) of substantial shareholder(s):
(as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company

Name	Nature of interest	No. of ordinary shares of the Company (the "Shares") held	Approximate percentage of total issued share capital of the Company
Genius Lead Limited ("Genius Lead")	Beneficial owner	529,500,546	54.97%
Genius Earn Limited ("Genius Earn") (Note 1)	Interest of a controlled corporation	529,500,546	54.97%
Mr. LIU Xiaolin ("Mr. Liu") (Note 2)	Interest of a controlled corporation and beneficial owner	529,750,546	55.00%

Notes:

1. Genius Lead is wholly-owned by Genius Earn. As such, Genius Earn is deemed to be interested in the shares of the Company which Genius Lead is interested in.
2. Mr. Liu is interested in 250,000 Shares as beneficial owner. Additionally, Genius Earn is wholly-owned by Mr. Liu. Mr. Liu is therefore deemed to be interested in the shares of the Company which Genius Earn is interested in.

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:

N/A

Financial year end date:

31 December

Registered address:

Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda

Head office and principal place of business:

Suites 1904-05A, 19/F, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong

Web-site address (if applicable):

www.cbshhk.com

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Share registrar:

Principal Share Registrar and Transfer Office

Conyers Corporate Services (Bermuda) Limited
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Hong Kong Branch Share Registrar and Transfer Office

Union Registrars Limited
Suites 3301-04, 33/F.
Two Chinachem Exchange Square
338 King's Road
North Point
Hong Kong

Auditors:

RSM Hong Kong
29th Floor, Lee Garden Two
28 Yun Ping Road, Causeway Bay, Hong Kong

B. Business activities

(Please insert here a brief description of the business activities undertaken by the Company and its subsidiaries.)

The principal activity of the company is investment holding. The principal activities of its subsidiaries are (i) provision of medical laboratory testing services and health check services in Hong Kong; (ii) provision of tumor immune cell therapy and health management services in the People's Republic of China (the "PRC"); (iii) sale and distribution of health related and pharmaceutical products in the PRC and Hong Kong; and (iv) provision of insurance brokerage services.

C. Ordinary shares

Number of ordinary shares in issue: 963,231,150

Par value of ordinary shares in issue: HK\$0.10

Board lot size (in number of shares): 5,000 shares

Name of other stock exchange(s) on which ordinary shares are also listed: N/A

D. Warrants

Stock code: N/A

Board lot size: N/A

Expiry date: N/A

Exercise price: N/A

Conversion ratio: N/A

(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding: N/A

No. of shares falling to be issued upon the exercise of outstanding warrants: N/A

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

Share Options

There are 4,740,000 outstanding Share options granted to certain eligible participants who include certain directors of the Company on 20 August 2019 under the share option scheme adopted by the Company pursuant to an ordinary resolution passed by the shareholders of the Company on 29 May 2014 (the "Share Option Scheme"), which are exercisable from 20 August 2022 to 19 August 2023 at an exercise price of HK\$1.68 per Share.

There are 6,440,000 outstanding Share options granted to an eligible participant who is a director of the Company on 2 September 2020 under the Share Option Scheme, which are exercisable from 2 September 2022 to 1 September 2024 at an exercise price of HK\$2.00 per Share.

There are 3,335,000 outstanding Share options granted to an eligible participant on 26 November 2020 under the Share Option Scheme, which are exercisable from 26 November 2022 to 25 November 2024 at an exercise price of HK\$2.10 per Share for Share options exercisable from 26 November 2022 to 25 November 2023; and HK\$2.20 per Share for Share options exercisable from 26 November 2023 to 25 November 2024.

There are 5,000,000 outstanding Share options granted to an eligible participant who is a director of the Company on 6 January 2023 under the Share Option Scheme, which are exercisable from 6 January 2024 to 5 January 2027 at an exercise price of HK\$1.45 per Share.

Convertible Bonds

On 30 December 2022, convertible bonds in the aggregate principal amount of US\$10,000,000 (the "Convertible Bonds") were issued by the Company to Guoyuan Securities Investment (Hong Kong) Limited (the "Subscriber") pursuant to the subscription agreement dated 20 December 2022 entered into between the Company and the Subscriber. Based on the initial conversion price of HK\$1.45 per conversion share at the exchange rate of HK\$7.85 to US\$1.00, a maximum number of 54,137,931 conversion shares of the Company will be allotted and issued upon exercise of the conversion rights attached to the Convertible Bonds in full.

As at the date hereof, US\$10,000,000 of the principal amount of the Convertible Bonds remains outstanding. The maturity date of the Convertible Bonds is 29 December 2024.

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Submitted by: LIU Xiaolin
(Name)

Title: Director
(Director, secretary or other duly authorised officer)

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.